Anzeige
Mehr »
Freitag, 29.08.2025 - Börsentäglich über 12.000 News
Megatrend Uran: Die Nachfrage nach Uran explodiert - greift jetzt Buffetts Erfolgsrezept?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHDZ | ISIN: AU0000043945 | Ticker-Symbol: PBN
Frankfurt
29.08.25 | 08:03
0,006 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ALTERITY THERAPEUTICS LIMITED Chart 1 Jahr
5-Tage-Chart
ALTERITY THERAPEUTICS LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0060,01014:40

Aktuelle News zur ALTERITY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02:17ALTERITY THERAPEUTICS LIMITED: Corporate Governance Statement1
02:14ALTERITY THERAPEUTICS LIMITED: Appendix 4G1
01:49ALTERITY THERAPEUTICS LIMITED: Appendix 4E and 2025 Annual Report-
22.08.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
22.08.ALTERITY THERAPEUTICS LIMITED: Application for quotation of securities - ATH-
15.08.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
15.08.ALTERITY THERAPEUTICS LIMITED: Notification regarding unquoted securities - ATH-
ALTERITY THERAPEUTICS Aktie jetzt für 0€ handeln
15.08.ALTERITY THERAPEUTICS LIMITED: Notification regarding unquoted securities - ATH-
04.08.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer-
04.08.ALTERITY THERAPEUTICS LIMITED: Response to ASX Query Letters-
31.07.ALTERITY THERAPEUTICS LIMITED: Updated Corporate Presentation-
30.07.ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q4 FY25 Quarterly Cash Flow Report130Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented...
► Artikel lesen
30.07.ALTERITY THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report2
28.07.ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer1
28.07.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy264- ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms - - Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy...
► Artikel lesen
28.07.Alterity Therapeutics Confirms Effectiveness of ATH434 Drug Against Advanced MSA1
28.07.Alterity Therapeutics Announces Positive Results from ATH434 Phase 2 Trial in Multiple System Atrophy6
28.07.ALTERITY THERAPEUTICS LIMITED: Positive ATH434 Results from Open-Label Phase 2 Trial in MSA-
28.07.ALTERITY THERAPEUTICS LIMITED: Change in substantial holding1
24.07.ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study4
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1